Skip to main content

Peer Review reports

From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Original Submission
13 Jan 2016 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
20 Aug 2016 Editorially accepted
31 Aug 2016 Article published 10.1186/s12885-016-2736-9

You can find further information about peer review here.

Back to article page